PBAC's latest decision on Molnupiravir: Recommended with restriction (2023). Considered for Treatment of patients with mild to moderate COVID-19 who are at high risk of severe disease requiring hospitalisation, including those aged ≥70 years, those aged ≥50 years with two or more risk factors or prior hospitalisation, immunocompromised patients, and Aboriginal or Torres Strait Islander people aged ≥30 years with one or more risk factors.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults with mild to moderate COVID-19 at high risk of progression to severe disease: (i) people aged ≥70 years; (ii) people aged ≥50 years with two or more risk factors or past COVID-19 infection resulting in hospitalisation; (iii) people aged ≥18 years who are moderately to severely immunocompromised or previously hospitalised; and (iv) Aboriginal or Torres Strait Islander people aged ≥30 years with one or more risk factors.
Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
Other
Key trials
MOVe-OUT
Comparator
usual care excluding use of antiviral treatments
Economic model
CUA
ICER note
This is a Category 2 (minor) submission for maintenance of existing listing with price reduction only; no new economic evaluation was conducted or reported in this PSD.